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Abstract Many studies have evaluated the performance
of risk assessment models for BRCA1/2 mutation carrier
probabilities in different populations, but to our knowledge
very few studies have been conducted in the German
population so far. In the recent study, we validated the
performance of three risk calculation models by names
BRCAPRO, Myriad and BOADICEA in 183 German
families who had undergone molecular testing of mutations
in BRCA1 and BRCA2 with an indication based on clinical
criteria regarding their family history of cancer. The sen-
sitivity and speciﬁcity at the conventional threshold of 10%
as well as for a threshold of 20% were evaluated. The
ability to discriminate between carriers and non-carriers
was judged by the area under the receiver operating char-
acteristics curve. We further focused on the performance
characteristic of these models in patients carrying large
genomic rearrangements as a subtype of mutations which is
currently gaining increasing importance. BRCAPRO and
BOADICEA performed almost equally well in our patient
population, but we found a lack of agreement to Myriad.
The results obtained from this study were consistent with
previously published results from other population and
racial/ethnic groups. We suggest using model speciﬁc
decision thresholds instead of the recommended universal
value of 10%. We further suggest integrating the CaGene5
software package, which includes BRCAPRO and Myriad,
in the genetic counselling of German families with sus-
pected inherited breast and ovarian cancer because of the
good performance of BRCAPRO and the substantial ease
of use of this software.
Keywords BOADICEA  BRCA1  BRCA2 
BRCAPRO  LGRs  Myriad
Introduction
Breast cancer (BC) is the most frequently diagnosed type of
cancer and the leading cause of cancer deaths of females in
industrialized nations. Incidence rates are increasing in
Germany, but sharply decreasing in other countries like the
USA, UK, France and Australia since the beginning of the
millennium [1]. The sharp reduction in BC incidence in
thesecountriesmayberelatedtoanationaldeclineintheuse
of hormone replacement therapy (HRT) after publishing the
results of the women’s health initiative (WHI) randomized
trials of HRT use in 2002. Interestingly, the reduction in BC
incidence was most pronounced in countries where peak
prevalence of HRT use was quite high [2]. However, BC
death rates have been decreasing in North America and
several European countries over the past 25 years [3, 4].
The authors S. M. Schneegans and A. Rosenberger contributed
equally to this work.
Electronic supplementary material The online version of this
article (doi:10.1007/s10689-011-9498-y) contains supplementary
material, which is available to authorized users.
S. M. Schneegans  U. Engel  M. Shoukier (&)
Institute of Human Genetics, University Medical Center, Georg
August University Go ¨ttingen, Heinrich-Du ¨ker-Weg 12,
37073 Go ¨ttingen, Germany
e-mail: moneef.shoukier@med.uni-goettingen.de
A. Rosenberger
Department of Genetic Epidemiology, University Medical
Center, Georg August University Go ¨ttingen, Humboldtallee 32,
37073 Go ¨ttingen, Germany
M. Sander  G. Emons
Department of Gynecology and Obstetrics, University Medical
Center, Georg August University Go ¨ttingen,
Robert-Koch-Strasse 40, 37075 Go ¨ttingen, Germany
123
Familial Cancer (2012) 11:181–188
DOI 10.1007/s10689-011-9498-yUpto 5–10% of BC cases can be attributed to individuals
with hereditary breast and ovarian cancer (HBOC). Unam-
biguously deleterious mutations in BRCA1 (MIM# 113705)
and BRCA2 (MIM# 600185) contribute to BC and other
associated tumors in large numbers of HBOC families [5].
The contribution of further tumor suppressor genes like p53
(MIM# 191140); PTEN (MIM# 601728), ATM (MIM#
208900) and RAD51C (MIM# 613399) to cancers in HBOC
isverylow[6,7].TheprevalenceofBRCA1orBRCA2germ
line mutations varies widely among populations [8]. Iden-
tifying a person at high risk of carrying a BRCA1 or BRCA2
mutation on the basis of his familial pedigree poses a big
challenge for the genetic counsellors. A common approach
is the estimation of the carrier probability based on the
familial history of a counselee, dealing especially with the
numberoffamilymembersaffectedbybreastand/orovarian
cancer and the age of onset. Many European countries like
UK, France, the Netherlands and Germany has established
its own indication criteria and recommendations for genetic
testing [9]. If families or single affected individuals fulﬁl
these inclusion criteria for mutation screening, the molecu-
lar genetic analysis is offered. Several empiric and com-
puter-based risk assessment models for BRCA1/2 mutation
carrier probabilities have been developed to assist in pretest
counseling, but independent validations of the performance
of such models has produced variable results [10].
BRCA gene mutation probability thresholds used to
establish the indication to perform DNA-analysis vary
considerably among countries. In Germany the molecular
genetic testing is recommended for families in which the
mutation probability is 10% or larger [11]. The German
consortium for hereditary breast and ovarian cancer (GC-
HBOC) established clinical guidelines for genetic testing in
suspected families based on their cancer history (Table 1).
These guidelines obviously provide a rough estimation of
the individual risk based on the results of empirical studies
without any consideration of the degrees of relationship
among affected family members, whereas mutation prob-
ability models are especially helpful to assess the individ-
ual carrier probability which underlies external variables
such as pattern of inheritance, kind of tumors in family
history, age-dependent incomplete penetrances, etc. [12].
However, mutation probability models have shown con-
siderable discrepancies in performance across different
racial/ethnic groups [13]. The aim of the present study is
two-fold: (a) to compare performance and clinical appli-
cability of three prediction models that performed best in
former international studies in order to ﬁnd the one that
could best be integrated into the clinical course of our
breast cancer consultancy, (b) To assess the performance
characteristic of these models in patients carrying BRCA1-
or BRCA2- large genomic rearrangements (LGRs), as a
subtype of easily detectable Mutations.
Materials and methods
Study population
Our study sample comprises all patients that attended
interdisciplinary breast cancer consultancy in the Breast
Cancer Center at the University Medical Center of Go ¨t-
tingen between 1999 and 2009. In total, we retrospectively
analysed data of 183 unrelated families for which at least
one affected member (the so called index-patient) was
tested for mutations in the BRCA1 and BRCA2 genes. All
these families met the inclusion criteria for genetic testing
according to the clinical guidelines of GC-HBOC [14, 15].
The patient record is compiled by a genetic consultant
and contains a complete personal medical history, the
informed consent for molecular analysis, a three generation
family pedigree as well as tumor and therapy related
information. Diagnoses were conﬁrmed using hospital
records and pathology reports in most instances. Coun-
selee’s ﬁrst and second degree affected relatives were
asked, when possible, to sign an informed consent to release
their medical records. Both affected men and women were
included in the study. Individuals with ductal carcinoma in
situ (DCIS) were entered into the models as having had
invasive BC [16]. Fallopian tube or peritoneal cancer were
counted same as OC [17]. Individuals carrying an unam-
biguously deleterious mutation were exclusively considered
to be BRCA1 or BRCA2 positive. Variants of unspeciﬁed
signiﬁcance (UVS) were assumed to be negative test results.
The study was approved by the local ethical committee.
Mutation testing
Until 2005, molecular testing was accomplished using
the denaturing high-performance liquid chromatography
Table 1 Indication for molecular testing based on clinical features of
the individual’s family history of cancer by the German consortium
for hereditary breast and ovarian cancer (GC-HBOC)
Number of affected
relatives
Indication for performing DNA-analysis
1
aB C B 35 years
b Bilateral BC B 50 years
c BC and OC
d BC/OC and male BC in the family
2
a Two cases of BC/OC, one case\51 years
b Two cases OC
c One case BC and one case OC
3
a Three cases of BC
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123(DHPLC) method (group 1, 61 families). From 2005, direct
DNA-sequencing was performed (group 2, 122 families). In
the latter group, a subsequent multiplex ligation dependent
probe ampliﬁcation (MLPA) analysis for LGRs in case of
negative sequencing results was carried out. The detected
rearrangements were conﬁrmed by using quantitative real-
time polymerase chain reaction (QRT-PCR). All mutations
and genetic variables were classiﬁed according to the breast
cancer information core (BIC) database (http://research.
nhgri.nih.gov/bic/) as well as to the human gene mutation
database (HGMD, available at: http://www.biobaseinter
national.com/Pages/index.php?id=hgmddatabase).
Mutation probability methods
The individual risk of carrying a BRCA1 or BRCA2
mutation was calculated for each patient by applying the
three different models. The calculations for Myriad and
BRCAPRO were carried out by using CaGene5 software
package (http://www4.utsouthwestern.edu/breasthealth/cag
ene/). For BOADICEA, the corresponding software can be
run online on the Cambridge University website (http://
www.srl.cam.ac.uk/genepi/boadicea/boadicea_intro.html).
Statistical analysis
To evaluate the strength of the pairwise correlation
between risks calculated by each model, we considered
bias corrected Spearman’s rank correlation coefﬁcients
with exact 95% conﬁdence intervals. To assess the agree-
ment of classiﬁcation, exceeding concordance by chance,
we calculated kappa coefﬁcients for decision thresholds of
10 and 20%. To evaluate the models’ ability to discrimi-
nate between mutation positive and negative individuals,
we constructed sensitivity, speciﬁcity and ROC curves.
Conﬁdence intervals (CI) for sensitivity and speciﬁcity
where derived by the method of Pearson and Clopper.
ROC-curves were plotted and compared by means of AUC
(area under the curve) according the method of DeLong
[18], setting the level of signiﬁcance to 5%. CI of thresh-
olds given speciﬁc values of sensitivity or speciﬁcity cover
all observed thresholds, where the value is included in the
conﬁdence interval of the considered measure. All calcu-
lations were performed using SAS 9.2 or standard pro-
grams for R.
Results
DNA mutational analysis
Out of the 183 families that underwent BRCA1 and BRCA2
mutation testing, 48 families (26.2%) showed a deleterious
BRCA-mutation. 35 families (19.1%) held a mutation in
BRCA1 including 3 LGRs; and 13 families (7.1%) held a
mutation in BRCA2 including 2 LGRs. The most frequently
detected mutation was the c.5382insC in exon 20 of
BRCA1 (8 families) followed by the mutation c.185delAG
in exon 2 of BRCA1 which was found in 4 families. The
whole mutations detected in our patient collective listed
with family members affected by breast and/or ovarian
cancer with age at diagnosis and personal risk ﬁgures
calculated by BRCAPRO, BOADICEA and Myriad are
given in Online Resource 1.
Correlation and agreement of calculated risk
The risks calculated by BRCAPRO and BOADICEA were
found to be strong correlated in mutation carriers
(r = 0.93) and in non-carriers (r = 0.81), although a little
less distinct in the latter. But risks calculated by Myriad
show only a weak correlation to those of BOADICEA and
BRCAPRO (Table 2). Typically the risks calculated by
Myriad were lower than by those of BRCAPRO and
BOADICEA, in mutation carrier (avg. risks: 28.65, 61.8
and 57.9%) as in non-carrier (avg. risks: 9.5, 17.3 and
17.8%). It can be seen from Fig. 1 that Myriad assigns the
same risk to groups of individuals, where the other methods
calculate wider ranges of risks.
Regardless the high correlation of BRCAPRO with
BOADICEA, the agreement of classiﬁcation between these
two at a decision threshold of 10% reaches 83% (95% CI:
61–100%) in mutation carrier but only 74% (95% CI:
62–86%) in non-carrier. In other words, there is still a
noticeable amount of individuals classiﬁed differently by
BRCAPRO and BOADICEA (2 of 48 mutation carriers and
19 of 135 non-carriers). The agreement of classiﬁcation
compared to MAYRIAD was moderate (about 50%) in
mutation carrier and lower than 35% in non-carrier
(Table 2).
Performance at pre-speciﬁed thresholds
Applying a decision threshold of 10% yielded a sensitivity
of about 85% for all three methods, meaning that a genetic
test was recommended to 41 or 42 of all 48 mutation
carriers. On the other hand Myriad showed the largest
speciﬁcity (67, 95% CI: 59–75%), meaning that genetic
testing was recommended to 44 of all 135 non-mutation
carriers. For BRCAPRO and BOADICEA (speciﬁcity of 62
and 56%) these were 51 and 60 non-mutation carriers
respectively, hence an increase in 16 or 36% of unneces-
sary recommended genetic testing (Table 2).
Considering a decision threshold of 20%, the sensitivity
of the methods decreases while the speciﬁcity increases as
expected. For BRCAPRO and BOADICEA, we noticed
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123small changes only (sensitivity: about -4-points, speciﬁty:
about ?10-points). But for Myriad a remarkable reduction
to 48% true positive rate together with a true negative rate
of 94% were found.
In applying this threshold to BRCAPRO and BOADI-
CEA, one would unnecessarily recommend genetic testing
for 38, respectively 41, of all 135 non-carriers. Using
Myriad, there were 8 non-carriers only. On the other hand,
using Myriad, no genetic test would be recommended for
25 of all 48 mutation carriers, while using BRCAPRO or
BOADICEA, there were only 9 mutation carriers.
Discrimination ability
Comparing ROC-curves of the three methods does not
reveal a signiﬁcant difference in the overall ability to dis-
criminate individuals at elevated and non-elevated risk
(P = 0.5391) based on the sample at hand (Fig. 2). Hence
we could not observe in general any advantage in sensi-
tivity (true positive rate) given a false positive rate (spe-
ciﬁty) for any of the methods. But the decision thresholds
to achieve a certain couple of sensitivity/speciﬁcity vary
noticeable, the lower the target false positive rate.
For a nominal speciﬁcity of 50%, a threshold of 9.2%
needs to be applied using BOADICEA, 8.7% in using
Myriad and 5.5% in using BRCAPRO, respectively. In
doing so, a true positive rate of about 90% can be expected.
But for a nominal speciﬁcity of 90% (genetic testing will
be recommended to only 10% of non-mutation carriers), a
threshold of 46% needs to be applied using BOADICEA,
18% in using Myriad and 53% in using BRCAPRO,
respectively. The expected true positive will then range
roughly between 50 and 60%. Vice versa, if one aims
sensitivity of e.g. 80%, the decision threshold to apply for
BOADICEA will be 22% and for BRCAPRO 26%. For
Myriad the estimated threshold is signiﬁcantly lower at
13% (95% CI: 8.7–16%).
We found that a small change in the decision threshold
has much more effect on the discrimination characteristics
for Myriad than for BRACAPRO or BOADICEA (Table 3;
Fig. 3). To achieve the same values in sensitivity or
speciﬁcity, the thresholds for Myriad need to be smaller
Table 2 Sensitivity and
speciﬁcity of all three programs
at a threshold of 10 and 20%
Threshold BRCAPRO BOADICEA Myriad
Mutation carrier, N = 48
Sensitivity % (95% CI)
10 85 (72–94) 85 (72–94) 88 (75–95)
20 81 (67–91) 81 (67–91) 48 (33–63)
Average of calculated risk 61.8 (52–72) 57.9 (48–68) 28.6 (22–35)
Correlation to
BRCAPRO 1
BOADICEA 0.93 (0.88–0.96) 1
Myriad 0.56 (0.33–0.73) 0.65 (0.45–0.79) 1
Inter-method agreement (kappa) at threshold 10%
BRCAPRO 1
BOADICEA 83% (61–100%) 1
Myriad 56% (21–90%) 56% (21–90%) 1
Mutation non-carrier, N = 135
Speciﬁcity % (95% CI)
10 62 (53–70) 56 (47–64) 67 (59–75)
20 72 (63–79) 70 (61–77) 94 (89–97)
Average of calculated risk 17.3 (14–21) 17.8 (14–21) 9.5 (8–11)
Correlation to
BRCAPRO 1
BOADICEA 0.81 (0.74–0.86) 1
Myriad 0.42 (0.27–0.55) 0.32 (0.16–0.46) 1
Inter-method agreement (kappa) at threshold 10%
BRCAPRO 1
BOADICEA 74% (63–86%) 1
Myriad 34% (17–50%) 26% (10–42%) 1
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123than for the other two methods, with the exception of
requested high sensitivity/low speciﬁcity.
Large genomic rearrangements (LGRs)
We separately evaluated the risk values of the 5 probands
carryingaLGR.Thethreeprobandsthatcarryalargedeletion
orduplicationinBRCA1exhibiteda high(C70%)riskproﬁle
in BRCAPRO (71, 97 and 100%, respectively). Likewise
BOADICEA calculated high risk values (84.5, 97 and
99.97%), whereas Myriad assessed rather moderate (C30 to
\70%)riskﬁguresfortheseindividuals(39.2,39.2and79%).
For the carrier of the exon 15–16, duplication in BRCA2
both BRCAPRO and BOADICEA calculated moderate risk
values (34.2 and 25.77%, respectively) while Myriad
assessed a false negative risk \10% (8.7%). For the last
proband who carries the BRCA2 exon 22–27 deletion, none
of the models computed an over 10% elevated risk (BRC-
APRO: 1.5%, BOADICEA: 1.66% and Myriad: 4.5%).
Discussion
We conducted the current study to evaluate the perfor-
mance and elucidate the clinical practicability of the
Fig. 1 Scatterplots: the risk
stratiﬁcations of the three
programs. Risk where
transformed to logits for a more
detailed presentation of small
values
Fig. 2 ROC curves: application of sensitivity against 1-speciﬁcity of
BRCAPRO, BOADICEA and Myriad
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123above-described assessment models for mutation carrier
probabilities in 183 German families previously tested for
mutations in BRCA1 and BRCA2 gene. Many studies have
been carried out to evaluate the performance of such
models in different populations [19–23], but very few
studies dealt with their reliability and applicability in the
German population so far [24, 25].
We obtained a mutation detection rate of 26%, which is
comparable to the mutation detection rate of GC-HBOC of
27% [26]. The most frequently detected mutation was the
BRCA1 c.5382insC mutation known to be frequent in
German BC patients [27] and displays the second most
described mutation in the BIC database. Furthermore, the
mutation c.185delAG in exon 2 of BRCA1 was found 4
times in our patient population. It is described as an
Ashkenasim Jewish founder mutation [28], but was also
found frequently in other racial/ethnic groups [29, 30].
It is also the most listed mutation of BRCA1 in the BIC
database. Unfortunately we cannot reconstruct the pro-
portion of consulters who are from Ashkenasim Jewish
descent.
At the recommended universal decision threshold of
10%, all three methods are comparable in terms of sensi-
tivity (about 85%). All models demonstrated a strong
ability to discriminate between carriers and non-carriers
with an area under the ROC (AUC) between 0.77 and 0.80
(Fig. 2). Our results are consistent with previously pub-
lished results from other population and racial/ethnic
groups which showed reasonably similar performance and
AUCs of all the models [12–16].
Table 3 model speciﬁc decision thresholds to achieve given sensitivity or speciﬁcity for both mutation and non-mutation carriers
Nominal speciﬁcity % Threshold % (95% CI) Sensitivity %
BOADICEA BRCAPRO Myriad BOADICEA BRCAPRO Myriad
50 9.2 (7.1–11) 5.5 (3.7–8.8) 8.6 (6.8–8.8) 87.5 90.0 90.0
60 11.6 (9.4–19) 9.4 (6.0–17) 8.7 (8.0–11) 85.4 85.4 90.0
70 22 (13–30) 19 (11–33) 12.2 (8.7–16) 81.3 81.3 81.3
80 30 (25–39) 35 (22–47) 15.9 (15–16) 70.8 70.8 62.5
90 46 (38–67) 53 (39–76) 18 (16–21) 60.4 64.6 47.9
Nominal sensitivity % Threshold % (95% CI) Speciﬁcity %
BOADICEA BRCAPRO Myriad BOADICEA BRCAPRO Myriad
50 67 (37–85) 69 (51–88) 18 (16–33) 94.1 92.6 93.3
60 47.9 (29–77) 62.0 (28–82) 16.9 (16–21) 90.4 91.9 88.9
70 30.4 (13–51) 39.8 (13–67) 15.9 (12–17) 80.0 84.4 88.1
80 22 (5.0–32) 26 (5.4–40) 13 (8.7–16) 70.4 75.6 72.6
90 5.0 (0.6–22) 5.4 (0.7–25) 8.7 (2.9–12) 30.4 48.9 65.2
Fig. 3 Sensitivity and
speciﬁcity of BRCAPRO,
BOADICEA and Myriad
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123The exclusion of a high proportion of non-mutation
carriers from expensive molecular analysis is thought to be
an advantage of the risk stratifying programs over clinical
guidelines. At the decision threshold of 10%, genetic tests
would not be recommended to between 55 and 67% of all
non-mutation carriers. The models would help in such a
way as to save the limited healthcare resources [31]. On the
other hand, a primary disadvantage is their consistent
tendency to underpredict the number of mutations in
families with low a priori risk [21].
The speciﬁcity of the models could be increased by
choosing a higher threshold level which would admittedly
go along with a loss of sensitivity and simultaneously the
occurrence of more false negative test results (mutation
carriers with a risk \10%). We found that the methods
behave quite differently in such a change of the cut-off
point. At a universal decision threshold of 20%, the
empirical model Myriad showed a sensitivity of 95%,
while only every second mutation carrier would be detec-
ted. The two mathematical models (BRCAPRO and BO-
ADICEA) showed only an inert change in their ability to
discriminate.
The median mutation probabilities in our patient popu-
lation differ between the two mathematical models and the
empirical model (Table 2). The high correlation between
BRCAPRO and BOADICEA and the weak correlation to
Myriad support this picture (Fig. 1). In contrast to the other
two programs, Myriad stratiﬁes the consulter’s risk on the
basis of a strongly condensed family history and allocates it
into several risks categories. Thus for several individuals,
the same risk value is predicted by this program. This
circumstance becomes visually clear in Fig. 1 as the risk
values were assessed by Myriad are situated in groups.
The imperfect agreement within calculated risks of BC
indicates that the use of an universal decision threshold for
any model, as the recommended 10% threshold of GC-
HBOC, can lead to quite different conclusions. The cal-
culated risks should not be considered as solely based on
the family history but also on the mathematical rules and
the model used. Our data show that an appropriate decision
threshold should be derived from diagnostic accuracy
measures rather than deﬁned directly by any BC risk. From
a clinical point of view, a high sensitivity, i.e. detecting a
higher number of mutation carriers, is more important than
a high speciﬁcity which would economically reduce
expenses for molecular analysis. For instance, if one seeks
a sensitivity of 80%, a threshold of *25% for BRCAPRO
and BOADICEA would be equivalent to a threshold of
13% for Myriad. This is accompanied by a speciﬁcity of
*75%. In contrast to the recommended threshold of 10%,
less mutation non-carriers will be sent to genetic testing by
almost comparable sensitivity.
The contribution of LGRs to the whole BRCA1/2
mutations varies widely among populations from almost no
presence in the African till 27% in the Dutch population. A
small to no contribution of BRCA2 LGRs in HBOC have
been reported in the majority of publications [32]. LGRs in
BRCA1 accounted for 9.6% of all BRCA1-mutations in the
study of Engert et al. on 1,506 German families with sus-
pected HBOC [33]. In the course of this study, a subgroup
of 412 high-risk individuals has been screened for LGRs in
BRCA2 with negative results. Veschi et al. have reported
that LGRs in BRCA1 are associated with high BRCAP-
RO—a priori risks [34]. To verify this hypothesis, we
separately evaluated the risk values of the 5 probands
carrying a LGR in our patients’ collective. Similar high
risk ﬁgures for the three BRCA1-LGRs-carriers have been
assessed by BRCAPRO and BOADICEA in our study.
Myriad has delivered moderately elevated risk ﬁgures for
these probands. Interestingly, two LGRs in the BRCA2
have been found in our collective (Online Resource 1). For
the previously described duplication of exon 15–16, the
three models assessed a moderate to low risk. For the other
patient who carries the novel deletion of exon 22–27, all
programs calculated false negative risk values. Indeed, she
had a negative family history concerning BRCA-associated
tumors. The indication for DNA analysis was the occur-
rence of BC at an age younger than 35 years (indication 1a,
Table 1). DNA samples from parents were not available for
testing on this deletion. Indeed, due to a small number of
detected LGRs in our study, a possible correlation between
this type of BRCA mutation and high or moderate a- priori
risk estimated by BRCAPRO and BOADICEA should be
interpreted with discretion. However, screening for LGR in
both BRCA1 and BRCA2 should be considered to complete
the genetic analysis in HBOC patients with no apparent
BRCA1/2 point mutations.
As there are no strong discrepancies in the performance
characteristic of these models, the ease of use gains a
strong impact for basing a decision as to which model
could be implied in the genetic counseling of German
families with suspected HBOC. We suggest integrating the
CaGene5 software package because of the good perfor-
mance of BRCAPRO and the substantially ease of use of
CaGene5 if compared with BOADICEA. The Myriad
model is included within this package so that there is a
double coverage in the case of uncertainty. Finally, to draw
more precise conclusions about LGRS, further studies with
larger number of BRCA 1\2 LGRs-carriers are needed.
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